Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Groningen – page 44

562 clinical trials in Groningen, The Netherlands across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Groningen at a glance
562
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

562 trials in Groningen

Open in trial search

Non-small cell lung cancer+1

Not recruiting

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Inflammatory bowel disease

Not recruiting

Study on the Safety and Imaging of Adalimumab-680LT for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Universitair Medisch Centrum Groningen

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Prophylaxis against transplant rejection

Not recruiting

Study on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Medical University Of Vienna

Gastrointestinal stromal tumour

Not recruiting

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Dementia Alzheimer's type

Not recruiting

Study on the Effects of JNJ-63733657 and Florquinitau F18 in Patients with Early Alzheimer's Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Posdinemab
  • Sponsor:Janssen Cilag International

Diffuse large B-cell lymphoma

Not recruiting

Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Infertility+2

Not recruiting

Study on Progesterone for Improving Birth Rates in Couples with Unexplained Infertility Undergoing Mild Ovarian Stimulation and Intrauterine Insemination

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Progesterone, Micronised
  • Sponsor:Universitair Medisch Centrum Utrecht

Systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide
  • Sponsor:Cogent Biosciences Inc.

Multiple sclerosis

Not recruiting

Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing Multiple Sclerosis Starting Anti-CD20 Therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Anti-glomerular basement membrane disease

Not recruiting

Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hansa Biopharma AB

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Groningen

What the registry says about research in the country

01 Cardiovascular Research

Advanced studies focusing on heart disease and cardiovascular conditions, including innovative treatments for ATTR amyloidosis and prevention strategies for heart failure.

  • Cardiomyopathy Treatments
  • Heart Failure Prevention
  • Peripheral Arterial Disease

Multiple trials exploring novel therapeutic approaches and preventive measures for various cardiac conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including melanoma and lung cancer, with particular focus on innovative treatment approaches and metastatic disease management.

  • Advanced Breast Cancer
  • Small Cell Lung Cancer
  • Brain Metastases

Investigation of targeted therapies and combination treatments for improved patient outcomes.

03 Metabolic Disorders

Clinical investigations focusing on obesity and type 2 diabetes, testing new therapeutic approaches for weight management and metabolic control.

  • Weight Management
  • Diabetes Treatment
  • Metabolic Health

Evaluation of novel medications combined with lifestyle interventions for optimal patient care.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.